glp-1 obesity drug market news today Receptor Agonists Drugs Size, Trends, Growth Report 2032 Goldman Sachs raises obesity drug

Obesity treatments using GLP-1 receptor agonists focus on weight management by promoting satiety, thereby reducing food intake and assisting in sustained weight loss

In a single-arm retrospective analysis by Firkins et al., clinical outcomes in GLP-1 RA users undergoing EGD were assessed [29]

Nonetheless, research focusing on their safety during pregnancy is scarce, with existing studies primarily addressing metabolic effects rather than gestational safety.224 Given that GLP-1/GIP dual agonists modulate multiple metabolic pathways, further research is necessary to elucidate their potential impact on fetal development.227 Additionally, safety assessments of GLP-1RAs and GLP-1/GIP dual agonists in non-pregnant women have identified common adverse reactions, including gastrointestinal discomfort and anorexia

PMC 12739101

Key Benefits - Marked reduction in body weight in clinical studies, with high-impact results in obesity

The underlying pathogenesis seems to be related to an inflammatory response to foreign microcapsules due to a potential deficiency of enzymes needed to break down the poly-(d,l-lactide- co -glycolide) material into lactic and glycolic acid [58,59,60]